Supreme Extends Due Diligence Period
04 Abril 2014 - 4:33PM
Marketwired
Supreme Extends Due Diligence Period
CALGARY, ALBERTA--(Marketwired - Apr 4, 2014) - Supreme
Pharmaceuticals Inc. (the "Company") (TSX-VENTURE:SL)(OTCBB:SPRWF)
reports that the parties have extended the due diligence period in
respect to the Company's peviously announced option agreement for
an additional 7 business days until April 10, 2014. While due
diligence results have been positive to date, the Company requires
additional time to ensure the proper assessment of the South
Okanagan producing facility before entering into the option.
President and CEO, David Stadnyk stated: "While we still believe
this will be a positive transaction for the Company and its
shareholders, these additional 7 days will give management the
appropriate amount of time to make the best decision for the
Company."
SUPREME PHARMACEUTICALS INC.
David Stadnyk, President & CEO
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
FORWARD LOOKING INFORMATION
This News Release contains forward-looking statements. The use
of any of the words "anticipate", "continue", "estimate", "expect",
"may", "will", "project", "should", "believe" and similar
expressions are intended to identify forward-looking statements.
Although the Company believes that the expectations and assumptions
on which the forward-looking statements are based are reasonable,
undue reliance should not be placed on the forward-looking
statements because the Company can give no assurance that they will
prove to be correct. Since forward-looking statements address
future events and conditions, by their very nature they involve
inherent risks and uncertainties. These statements speak only as of
the date of this News Release. Actual results could differ
materially from those currently anticipated due to a number of
factors and risks including various risk factors discussed in the
Company's disclosure documents which can be found under the
Company's profile on www.sedar.com. This News Release contains
"forward-looking statements" within the meaning of Section 27A of
the Securities Act of 1933, as amended, and Section 21E the
Securities Exchange Act of 1934, as amended and such
forward-looking statements are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of
1995.
Listed on the TSX Venture under the symbol ("SL")
Supreme Pharmaceuticals Inc.#772 Alastair Ross Technology
Centre3553 31st Street NW, Calgary Alberta, T2L 2K7(647)
340-6744info@supremepharmaceuticals.comwww.supremepharmaceuticals.com
(TSXV:SL)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
(TSXV:SL)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024